Which has preferable earnings and valuation, SKYE or DCOY?

Skye Bioscience is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$10.16 N/A Decoy Therapeutics N/A N/A -$12.52M -$30.37 N/A

Is SKYE or DCOY more profitable?

Decoy Therapeutics' return on equity of -315.22% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -329.08% -201.79% Decoy Therapeutics N/A -315.22% -167.15%

Does the media prefer SKYE or DCOY?

In the previous week, Skye Bioscience had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 12 mentions for Skye Bioscience and 11 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 0.26 beat Skye Bioscience's score of -0.22 indicating that Decoy Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Decoy Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DCOY or CODX?

In the previous week, Decoy Therapeutics had 6 more articles in the media than Co-Diagnostics. MarketBeat recorded 11 mentions for Decoy Therapeutics and 5 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.30 beat Decoy Therapeutics' score of 0.26 indicating that Co-Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Decoy Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BOLT or DCOY?

In the previous week, Bolt Biotherapeutics had 7 more articles in the media than Decoy Therapeutics. MarketBeat recorded 18 mentions for Bolt Biotherapeutics and 11 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 0.26 beat Bolt Biotherapeutics' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bolt Biotherapeutics 1 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Decoy Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, DCOY or ERNA?

Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$30.37 N/A Ernexa Therapeutics N/A N/A -$14.08M -$14.35 N/A

Is DCOY or ERNA more profitable?

Ernexa Therapeutics' return on equity of -305.93% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% Ernexa Therapeutics N/A -305.93% -169.86%

Does the media favor DCOY or ERNA?

In the previous week, Decoy Therapeutics had 9 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 11 mentions for Decoy Therapeutics and 2 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.89 beat Decoy Therapeutics' score of 0.26 indicating that Ernexa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Decoy Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DCOY or CDIO?

Decoy Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 870.87%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer DCOY or CDIO?

In the previous week, Decoy Therapeutics had 8 more articles in the media than Cardio Diagnostics. MarketBeat recorded 11 mentions for Decoy Therapeutics and 3 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.19 beat Decoy Therapeutics' score of 0.26 indicating that Cardio Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Decoy Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardio Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Decoy Therapeutics (DCOY) Competitors

$3.09 -0.02 (-0.64%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$3.09 0.00 (0.00%)

As of 09/25/2026 07:53 PM Eastern

Compare

DCOY vs. SKYE, CODX, BOLT, ERNA, and CDIO

Should you buy Decoy Therapeutics stock or one of its competitors? Decoy Therapeutics's main competitors and comparable companies include Skye Bioscience (SKYE), Co-Diagnostics (CODX), Bolt Biotherapeutics (BOLT), Ernexa Therapeutics (ERNA), and Cardio Diagnostics (CDIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Decoy Therapeutics compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Skye Bioscience is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A

In the previous week, Skye Bioscience had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 12 mentions for Skye Bioscience and 11 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 0.26 beat Skye Bioscience's score of -0.22 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Decoy Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Skye Bioscience has a beta of 2.9, meaning that its stock price is 190% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Decoy Therapeutics' return on equity of -315.22% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-329.08%	-201.79%
Decoy Therapeutics	N/A	-315.22%	-167.15%

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by company insiders. Comparatively, 1.5% of Decoy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Skye Bioscience currently has a consensus price target of $64.00, suggesting a potential upside of 3,732.34%. Decoy Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 870.87%. Given Skye Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Skye Bioscience is more favorable than Decoy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Skye Bioscience beats Decoy Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Decoy Therapeutics compare to Co-Diagnostics?

Decoy Therapeutics (NASDAQ:DCOY) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Decoy Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market.

In the previous week, Decoy Therapeutics had 6 more articles in the media than Co-Diagnostics. MarketBeat recorded 11 mentions for Decoy Therapeutics and 5 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.30 beat Decoy Therapeutics' score of 0.26 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Decoy Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 870.87%. Co-Diagnostics has a consensus price target of $67.50, suggesting a potential upside of 6,092.66%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Decoy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 1.5% of Decoy Therapeutics shares are held by insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Decoy Therapeutics has higher earnings, but lower revenue than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
Co-Diagnostics	$721.39K	10.55	-$46.90M	-$10.32	N/A

Decoy Therapeutics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Co-Diagnostics' return on equity of -210.99% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

Summary

Co-Diagnostics beats Decoy Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Decoy Therapeutics compare to Bolt Biotherapeutics?

Bolt Biotherapeutics (NASDAQ:BOLT) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 1.5% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bolt Biotherapeutics presently has a consensus price target of $14.50, suggesting a potential upside of 305.03%. Decoy Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 870.87%. Given Decoy Therapeutics' higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Decoy Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -126.23% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
Decoy Therapeutics	N/A	-315.22%	-167.15%

Decoy Therapeutics has lower revenue, but higher earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	0.90	-$33.38M	-$16.44	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A

In the previous week, Bolt Biotherapeutics had 7 more articles in the media than Decoy Therapeutics. MarketBeat recorded 18 mentions for Bolt Biotherapeutics and 11 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 0.26 beat Bolt Biotherapeutics' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bolt Biotherapeutics	1 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Decoy Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bolt Biotherapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Summary

Bolt Biotherapeutics beats Decoy Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Decoy Therapeutics compare to Ernexa Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Decoy Therapeutics had 9 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 11 mentions for Decoy Therapeutics and 2 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.89 beat Decoy Therapeutics' score of 0.26 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Decoy Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ernexa Therapeutics' return on equity of -305.93% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 870.87%. Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 759.85%. Given Decoy Therapeutics' higher possible upside, research analysts clearly believe Decoy Therapeutics is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
Ernexa Therapeutics	N/A	N/A	-$14.08M	-$14.35	N/A

Decoy Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.61, indicating that its share price is 161% more volatile than the broader market.

Summary

Decoy Therapeutics beats Ernexa Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Decoy Therapeutics compare to Cardio Diagnostics?

Decoy Therapeutics (NASDAQ:DCOY) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 1.5% of Decoy Therapeutics shares are held by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Decoy Therapeutics had 8 more articles in the media than Cardio Diagnostics. MarketBeat recorded 11 mentions for Decoy Therapeutics and 3 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.19 beat Decoy Therapeutics' score of 0.26 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Decoy Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardio Diagnostics has higher revenue and earnings than Decoy Therapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
Cardio Diagnostics	$14.45K	399.45	-$6.50M	-$2.92	N/A

Decoy Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Decoy Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 870.87%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Decoy Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market.

Summary

Cardio Diagnostics beats Decoy Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Decoy Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCOY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCOY vs. The Competition

Export

Metric	Decoy Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.02M	$3.94B	$7.33B	$13.17B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-0.10	14.15	275.82	25.78
Price / Sales	N/A	1,438.70	649.60	92.85
Price / Cash	N/A	120.91	79.52	52.89
Price / Book	0.28	15.28	10.44	6.30
Net Income	-$12.52M	-$22.90M	$3.51B	$360.35M
7 Day Performance	11.15%	-2.94%	-1.31%	-0.23%
1 Month Performance	4.04%	-8.80%	-4.61%	-4.16%
1 Year Performance	N/A	28.99%	15.01%	4.58%

Decoy Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCOY Decoy Therapeutics	3.0018 of 5 stars	$3.09 -0.6%	$30.00 +870.9%	N/A	$2.02M	N/A	N/A	11
SKYE Skye Bioscience	3.3015 of 5 stars	$1.77 +12.4%	$64.00 +3,526.1%	-94.9%	$6.95M	N/A	N/A	11	News Coverage Insider Trade Gap Up
CODX Co-Diagnostics	2.4199 of 5 stars	$0.95 +0.6%	$67.50 +7,037.6%	-90.5%	$6.56M	$620K	N/A	100	Gap Down
BOLT Bolt Biotherapeutics	2.5276 of 5 stars	$3.56 +6.3%	$14.50 +307.3%	-33.9%	$6.44M	$7.70M	N/A	90	Gap Down High Trading Volume
ERNA Ernexa Therapeutics	3.4611 of 5 stars	$3.82 +1.5%	$30.00 +686.4%	-87.8%	$6.14M	$580K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCOY) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Decoy Therapeutics (DCOY) Competitors

DCOY vs. SKYE, CODX, BOLT, ERNA, and CDIO

How does Decoy Therapeutics compare to Skye Bioscience?

Summary

How does Decoy Therapeutics compare to Co-Diagnostics?

Summary

How does Decoy Therapeutics compare to Bolt Biotherapeutics?

Summary

How does Decoy Therapeutics compare to Ernexa Therapeutics?

Summary

How does Decoy Therapeutics compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Decoy Therapeutics (DCOY) Competitors

DCOY vs. SKYE, CODX, BOLT, ERNA, and CDIO

How does Decoy Therapeutics compare to Skye Bioscience?

Which has preferable earnings and valuation, SKYE or DCOY?

Does the media prefer SKYE or DCOY?

Which has more volatility and risk, SKYE or DCOY?

Is SKYE or DCOY more profitable?

Do institutionals and insiders have more ownership in SKYE or DCOY?

Do analysts rate SKYE or DCOY?

Summary

How does Decoy Therapeutics compare to Co-Diagnostics?

Which has more volatility & risk, DCOY or CODX?

Does the media prefer DCOY or CODX?

Do analysts rate DCOY or CODX?

Do insiders & institutionals have more ownership in DCOY or CODX?

Which has better earnings & valuation, DCOY or CODX?

Is DCOY or CODX more profitable?

Summary

How does Decoy Therapeutics compare to Bolt Biotherapeutics?

Do institutionals and insiders have more ownership in BOLT or DCOY?

Do analysts recommend BOLT or DCOY?

Is BOLT or DCOY more profitable?

Which has stronger valuation and earnings, BOLT or DCOY?

Does the media refer more to BOLT or DCOY?

Which has more risk and volatility, BOLT or DCOY?

Summary

How does Decoy Therapeutics compare to Ernexa Therapeutics?

Does the media favor DCOY or ERNA?

Do insiders & institutionals believe in DCOY or ERNA?

Is DCOY or ERNA more profitable?

Do analysts rate DCOY or ERNA?

Which has stronger valuation and earnings, DCOY or ERNA?

Which has more risk and volatility, DCOY or ERNA?

Summary

How does Decoy Therapeutics compare to Cardio Diagnostics?

Do insiders and institutionals have more ownership in DCOY or CDIO?

Does the media prefer DCOY or CDIO?

Which has better valuation & earnings, DCOY or CDIO?

Is DCOY or CDIO more profitable?

Do analysts prefer DCOY or CDIO?

Which has more risk and volatility, DCOY or CDIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools